Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MMP1 | P03956 | 4/20 | 0.62 |
| ▸ | MMP2 | P08253 | 4/20 | 0.62 |
| ▸ | MMP9 | P14780 | 4/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209792 | 1.00 | PTGS2 (0.64) | PTGS2MAPTMEN1KMT2AMMP1 | |
| SCHEMBL4204101 | 0.89 | MMP1 (0.66) | MAPTMEN1KMT2AMMP1MMP2 | |
| SCHEMBL4204091 | 0.89 | MMP1 (0.66) | MAPTMEN1KMT2AMMP1MMP2 | |
| SCHEMBL1634811 | 0.87 | TRPV1 (0.62) | PTGS2MAPTMEN1KMT2AMMP1 | |
| SCHEMBL1634809 | 0.87 | TRPV1 (0.62) | PTGS2MAPTMEN1KMT2AMMP1 | |
| SCHEMBL1636207 | 0.85 | PTGS2 (0.53) | PTGS2MAPTMEN1KMT2AMMP1 | |
| SCHEMBL4211905 | 0.85 | CA12 (0.53) | PTGS2MAPTMEN1KMT2ACA12 | |
| SCHEMBL1636198 | 0.85 | PTGS2 (0.53) | PTGS2MAPTMEN1KMT2AMMP1 | |
| SCHEMBL4211914 | 0.85 | CA12 (0.53) | PTGS2MAPTMEN1KMT2ACA12 | |
| SCHEMBL4211206 | 0.84 | PTGS2 (0.52) | PTGS2MAPTMEN1KMT2AMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482488-B2 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-01-27 | — | — | US | claimed |
| EP-1539675-A4 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060167317-A1 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-07-27 | — | — | US | claimed |
| EP-1539675-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004037751-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2004-05-06 | — | — | WO | claimed |
| EP-1539675-B1 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7482488-B2 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1539675-A4 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060167317-A1 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1539675-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004037751-A2 | ARYL AND HETEROARYL PROPENE AMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167317-A1 | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | BCL2A1, NFE2L2, BCL2 | PTGS2 371/4885MAPT 4667/4885MEN1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.